Geode Capital Management LLC Has $7.19 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI

Geode Capital Management LLC increased its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 12.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,984,045 shares of the company’s stock after acquiring an additional 319,679 shares during the period. Geode Capital Management LLC owned about 1.17% of Maravai LifeSciences worth $7,193,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Nuveen LLC bought a new stake in Maravai LifeSciences during the 1st quarter worth approximately $666,000. Philosophy Capital Management LLC purchased a new position in shares of Maravai LifeSciences during the first quarter valued at approximately $5,731,000. Jacobs Levy Equity Management Inc. grew its holdings in Maravai LifeSciences by 437.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 493,582 shares of the company’s stock worth $1,091,000 after buying an additional 401,673 shares in the last quarter. Strs Ohio bought a new stake in Maravai LifeSciences during the first quarter worth $429,000. Finally, Parkman Healthcare Partners LLC raised its position in Maravai LifeSciences by 88.6% in the 1st quarter. Parkman Healthcare Partners LLC now owns 660,000 shares of the company’s stock valued at $1,459,000 after buying an additional 310,000 shares during the last quarter. Institutional investors own 50.25% of the company’s stock.

Insider Buying and Selling at Maravai LifeSciences

In related news, CEO Bernd Brust purchased 216,212 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was bought at an average price of $3.25 per share, for a total transaction of $702,689.00. Following the purchase, the chief executive officer directly owned 466,771 shares in the company, valued at approximately $1,517,005.75. This trade represents a 86.29% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have purchased 466,771 shares of company stock worth $1,511,699. 2.11% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on MRVI shares. Royal Bank Of Canada cut their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.36.

Maravai LifeSciences Stock Performance

NASDAQ MRVI opened at $3.70 on Friday. The stock has a market capitalization of $946.13 million, a price-to-earnings ratio of -4.40 and a beta of 0.33. Maravai LifeSciences Holdings, Inc. has a one year low of $1.66 and a one year high of $6.21. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56. The business’s fifty day moving average is $3.31 and its 200-day moving average is $2.75.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The company had revenue of $41.63 million for the quarter, compared to the consensus estimate of $49.02 million. Equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.